About us

We founded Endor in 2007 and have been dedicated to cancer research ever since. In 2016, to ensure the long-term viability of the company and accelerate our research, we decided to open a skin care pipeline where we apply the best of what we learned in medical research.

In our routines you can find the result of this research, with an efficacy that has earned the trust of the best aesthetic doctors and what is even more important, that of our clients.

Our hope is that the medical research we develop every day reaches you and contributes to make your life better.


  • Biotech product of the year. European Biotechnology Congress2016: "Cancer treatment through the use of immunostimulating proteins".

  • Award for the best innovative company 2014. University of Barcelona.

  • Innovative Company. Recognition granted by the Ministry of Economy and Competitiveness of the Government of Spain.

  • SME company at the EMA (European Medicines Agency).



  • "Proteins for use in cancer treatment". Querol Sastre J., SobrevalsL., Parkkola H., Vivero L., Miñana R., Sendra J. Application Number:15179043.3-1456. Applicant: Endor Technologies S.L.

  • "System for the release of a therapeutic agent, pharmaceuticalcomposition containing it, the preparation and medical use thereof".Querol Sastre J., Sendra Cuadal J., Vivero Sanchez L., Ramis CastelltortM., Parkkola H. International Publication Number WO 2012/089768-A1.Applicant: Endor Technologies, S.L.

  • "Conjugate of Hyaluronic Acid for Cosmetic Treatment and Preparation Method". Querol Sastre J., Ramis Castelltort M., Ojea Jimenez I.International Publication Number: WO 2009/087254-A1 Applicant: EndorTechnologies S.L.

  • "Metal nanoobjects for cosmetic use" Querol Sastre J, Escudero Cano J. Ref. P4212EP00. Applicant: Endor Technologies S.L.



  • "Advanced nanosystems based on gold nanoparticles and hyaluronic acid for dermatological and cosmetic applications". Author:Rafael Miñana Prieto. Director: Judith Sendra PhD.

  • "Hyaluronic acid-coated gold nanoparticles as an anticancer drugdelivery system - Biological characterization and efficacy". Author:Hanna Parkkola. Director: Judith Sendra PhD.

  • "Design and characterization of drug delivery systems based on metal nanoparticles and hyaluronic acid". Author: LauraVivero Sanchez. Director: Judith Sendra PhD.



  • "Nanotechnology: Recent Trends, Emerging Issues and Future Directions. Chapter: Nanomedicine: The New Age of Therapeutics".Sobrevals L., Parkkola H., Vivero L., Miñana R., Sendra J., 2014.Publisher: N. Nova Science Publishers, Inc.

  • "Converging hazard assessment of gold nanoparticles to aquaticorganisms". Jesús Pablo García-Cambero, Mercedes Núñez García, Gema DíazLópez, Ana López Herranz, Laureano Cuevas, Esperanza Pérez-Pastrana,Judith Sendra Cuadal, Marc Ramis Castelltort, Argelia Castaño Calvo.Chemosphere 93 (2013). 1194-1200.

  • "Proceed with caution? Concept and application of the precautionaryprinciple in nanobiotechnology: Gold Nanoparticles and Cell ViabilityEvaluation". Parkkola H., Vivero L., Ramis M., Querol J., Sendra J.,2012. Editors: Ach J.S., Lüttenberg B., Paslack R., Weltring K-M. LITVerlag

  • "Gold Nanoparticle Stability Studies in Physiological Media".Parkkola H., Vivero L., Ramis M., Cambero J.P.G., Querol J., Sendra J.,2012. Editors: Ach J.S., Lüttenberg B., Paslack R., Weltring K-M. LITVerlag.

  • "In Vitro Safety Toxicology Data for Evaluation of GoldNanoparticles-Chronic Cytotoxicity, Genotoxicity and Uptake". Claudia DiGuglielmo, Joaquín De Lapuente, Constança Porredon, David Ramos-López,Judith Sendra, and Miquel Borràs. Journal of Nanoscience and Nanotechnology. Vol. 12, 6185-6191, 2012.

  • "Embryotoxicity of cobalt ferrite and gold nanoparticles: A first invitro approach". Claudia Di Guglielmoa, David Ramos Lópeza, Joaquín DeLapuente, Joan Maria Llobet Mallafre, Miquel Borràs Suàreza.Reproductive Toxicology 30 (2010) 271-276.

  • "Metallic Nanoparticles and Cytotoxicity Assessment". Parkkola H.,Vivero L., Vega M., Ramis M., Querol Sastre J., Sendra J., 2010.International Congress of Toxicology.

  • "Instability of Cationic Gold Nanoparticle Bioconjugates: The Roleof Citrate Ions". Isaac Ojea-Jimenez, Victor Puntes. JACS-2009.



  • Project: "Cosmetic research with nanoparticles to treat facial melasma". Participant: Endor Technologies S.L. Funding: ACCIO. Year: 2014.

  • Project: "Development and clinical application of an oncological drug delivery system using nanoparticles" Participant: Endor Technologies S.L. Funding: Centro de DesarrolloTecnológico Industrial (CDTI). Year: 2011.

  • Project: "Sustainable Hydrothermal Manufacturing of Nanomaterials(SHYMAN)". Participants: Endor Technologies S.L., NottinghamUniversity, University of Valladolid, Instytut Wysokich Cisnien, DelftUniversity, Trinity College Dublin, GTVP, Promethean Particles, CentroRicerche FIAT, Akzo Nobel, Repsol, Solvay, Topgan, Itaprochim, LewarGmbH, Boots UK, Van Loon Chemical Innovations, Pielaszek Research,Ceramysis. Funding: European Commission, Seventh Framework Program. Year:2011.

  • Project: "Nanosost: Towards a Responsible and Safe Nanotechnology".Participants: Endor Technologies S.L., Ceretox, Instituto Carlos III, Leia, Inasmet, Solutex. Funding: Ministry of Science and Innovation. Year: 2008.

  • Project: "Design of nanoheat sources for cosmetic applications". Participants: Endor Technologies S.L., Institute of Photonic Sciences (ICFO). Funding: ACCIO. Year: 2008.

  • Project: "Synthesis of advanced nanomaterials for their application in nanomedicine: ferromagnetic structures and multiple conjugation" Participant: Endor Technologies S.L. Funding: Centro de DesarrolloTecnológico Industrial (CDTI). Year: 2007.

  • Project: "Synthesis of advanced nanomaterials for their application in nanomedicine: Nano Au-Co". Participants: Endor Technologies S.L., Catalan Institute of Nanotechnology. Funding: Ministry of Industry, Energy and Tourism. Year: 2007.